A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age

Summary

The purpose of this study is to learn about the safety and immune activity of the vaccine (called RSVpreF) in children 2 to \<18 years of age. This study will identify the dose level to be used in Phase 2/3 trials in this age cohort. All participants will receive one injection of RSVpreF. This study has four study visits, two in-clinic and two telehealth visits. Blood samples will be collected for testing. This study is about 6 months long for each participant and will be conducted in the United States.

Timeline

Start

2023-06-22

Primary completion

2024-02-29

Completion

2024-02-29

Drugs

Indications